Blueprint Medicines Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Blueprint Medicines (BPMC) Misses Q2 EPS by 14c
July 30, 2020 7:48 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($2.28), $0.14 worse than the analyst estimate of ($2.14). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $6.94 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
... More